TCE2.F Celldex Therapeutics Inc
- Market cap
- EUR 1.99B
- P/E
- -
- P/B
- 3.66x
- ROE
- -46.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is TCE2.F undervalued?
Graham numberThe Graham number of Celldex Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Celldex Therapeutics Inc fundamental analysis
No fundamental analysis for Celldex Therapeutics Inc yet.
Celldex Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT recep…
Full company profileCelldex Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Celldex Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.79M | 12.7M | 9.54M | 3.57M | 7.42M | 4.65M | 2.36M | 6.88M | 7.02M | 1.55M | 49.3K |
| Operating Income | -133M | -109M | -76.4M | -54.5M | -49.6M | -69.1M | -107M | -142M | -195M | -287M | -330M |
| EBITDA | - | -104M | -72.6M | -49.7M | -45.6M | -66.1M | -104M | -139M | -192M | -284M | -326M |
| Net Income | -129M | -93.0M | -151M | -50.9M | -59.8M | -70.5M | -112M | -141M | -158M | -259M | -304M |
| EPS | - | -10 | -13 | -3.00 | -1.51 | -1.51 | -2.38 | -2.53 | -2.38 | -3.89 | -3.87 |
| Balance Sheet | |||||||||||
| Total Assets | 383M | 316M | 156M | 123M | 236M | 445M | 353M | 466M | 792M | 583M | 722M |
| Total Liabilities | 118M | 79.3M | 31.7M | 28.9M | 26.5M | 25.2M | 26.5M | 36.5M | 45.3M | 55.8M | 72.1M |
| Shareholders' Equity | 265M | 236M | 124M | 94.0M | 209M | 419M | 326M | 429M | 747M | 527M | 649M |
| Cash & Short-term Investments | 42.5M | 40.3M | 24.3M | 11.2M | 43.8M | 39.1M | 29.4M | 34.8M | 28.4M | 28.9M | 27.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -113M | -99.9M | -75.2M | -46.4M | -40.4M | -60.9M | -104M | -107M | -158M | -211M | -251M |
| Capital Expenditure | 2.75M | 1.79M | 813K | 731K | 1.55M | 1.25M | 1.83M | 1.82M | 1.92M | 2.71M | 8.65M |
| Free Cash Flow | - | -102M | -76.0M | -47.1M | -42.0M | -62.2M | -106M | -109M | -160M | -214M | -259M |
| Ratios | |||||||||||
| ROE | -48.4% | -39.4% | -121.9% | -54.1% | -28.6% | -16.8% | -34.4% | -33.0% | -21.1% | -49.1% | -46.8% |
| ROA | -33.5% | -29.5% | -97.0% | -41.4% | -25.3% | -15.9% | -31.8% | -30.4% | -19.9% | -44.4% | -42.1% |
| Net Profit Margin | -1,894.0% | -730.1% | -1,585.1% | -1,424.0% | -805.9% | -1,516.0% | -4,765.6% | -2,054.8% | -2,248.8% | -16,748.0% | -615,527.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Celldex Therapeutics Inc dividends
Celldex Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Feb 11, 2019.
Who owns Celldex Therapeutics Inc
- Insiders 0.27%
- Institutions 99.73%
- Public & others 0.00%
- Shares outstanding 78.5M
- Free float 73.0M
Celldex Therapeutics Inc company profile
- Company name
- Celldex Therapeutics Inc
- Ticker
- TCE2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 198
- Fiscal year end
- December
- Address
- Perryville III Building, Hampton, NJ, United States, 08827
- Phone
- 908 200 7500
- Website
- celldex.com
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Celldex Therapeutics Inc management
10- Mr. Anthony S. Marucci M.B.A.Founder, President, CEO & Director · born 1962
- Dr. Tibor Keler Ph.D.Founder, Chief Scientific Officer & Executive VP · born 1959
- Mr. Sam Martin CPASenior VP, CFO, Secretary & Treasurer · born 1971
- Ms. Elizabeth CrowleyChief Product Development Officer & Senior VP · born 1972
- Dr. Margo Heath-Chiozzi M.D.Senior Vice President of Regulatory Affairs · born 1957
- Prof. Joseph P. Schlessinger Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1945
- Ms. Sarah CavanaughSenior Vice President of Corporate Affairs & Administration · born 1975
- Mr. Freddy A. Jimenez Esq.Senior VP & General Counsel · born 1969
- Dr. Ronald A. Pepin Ph.D.Chief Business Officer & Senior VP · born 1956
- Dr. Diane C. Young M.D.Senior VP & Chief Medical Officer · born 1957